妊娠期左乙拉西坦单药治疗如何监测?一项系统综述
研究发现癫痫监测、TDM策略和剂量调整存在显著异质性,妊娠期癫痫发作频率增加,但母胎安全性数据有限。目前无标准化TDM方案,需未来研究标准化策略并验证目标浓度阈值。
要点
- 妊娠期左乙拉西坦TDM策略异质性大,缺乏标准化方案。
- 妊娠期药代动力学变化可能降低左乙拉西坦水平,需剂量调整以控制癫痫。
- 左乙拉西坦母胎安全性数据有限,长期安全性待评估。
核心结论
- 妊娠期左乙拉西坦TDM策略存在显著异质性,无标准化方案。
- 妊娠期药代动力学变化需剂量调整以维持癫痫控制。
- 未来研究应标准化TDM策略、验证目标浓度阈值并评估长期母胎安全性。
研究设计与样本
- 系统综述,检索MEDLINE、Embase、APA PsycINFO和Cochrane CENTRAL(通过Ovid),截至2025年4月17日。
- 纳入标准为提供妊娠期左乙拉西坦剂量、浓度、监测、疗效或安全性数据的研究。
主要发现
- 描述到妊娠期癫痫发作频率增加。
- 左乙拉西坦母体和胎儿安全性数据有限。
临床怎么用
- 妊娠期应关注左乙拉西坦水平变化,考虑TDM辅助剂量调整以维持癫痫控制。
- 目前无标准化TDM方案,临床需个体化决策。
局限性
- 左乙拉西坦母胎安全性数据有限。
- 缺乏标准化TDM方案和目标浓度阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Levetiracetam is commonly used as antiepileptic drug during pregnancy and has a well-established safety profile in that setting. Pregnancy-related pharmacokinetic changes may result in decreased levetiracetam levels and increased seizure frequency during pregnancy. Therapeutic drug monitoring (TDM) of levetiracetam levels may facilitate dose adjustment. Although levetiracetam TDM is widely used in pregnancy, robust guidelines are still lacking, resulting in heterogeneous use of TDM. OBJECTIVES: The aim of this review was to provide insight into levetiracetam TDM strategies utilised during pregnancy. METHODS: A systematic search up to 17 April 2025 was carried out using MEDLINE, Embase, APA PsycINFO, and Cochrane Central Register of Controlled Trials through Ovid. Studies were eligible for inclusion if data on levetiracetam dosing, concentrations, monitoring, efficacy, or safety during pregnancy were available. All articles were assessed for the risk of bias, and relevant data were extracted. RESULTS: The ten studies included revealed significant variability in epilepsy monitoring during pregnancy, TDM strategies, and dose adjustments. An increase in seizure frequency during pregnancy was described. However, data on levetiracetam maternal and foetal safety were limited. CONCLUSIONS: This review highlights the heterogeneity in levetiracetam TDM strategies in pregnancy. The pharmacokinetic changes during pregnancy require dose adjustments to maintain seizure control, but no standardised TDM protocol is available. Future research should focus on standardizing TDM strategies, validating target concentration thresholds, and assessing long-term maternal and foetal safety.
引用
- Rademaker T, Goo Y, Soh MC, et al. How is Levetiracetam Monotherapy Currently Monitored in Pregnancy? A Systematic Review. Clin Pharmacokinet. 2025. PMID: 41120802. doi:10.1007/s40262-025-01580-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。